Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-κB and STAT3
The oncogenic microRNA-21 contributes to the pathogenesis of multiple myeloma. Ibrutinib (also referred to as PCI-32765), an inhibitor of Bruton’s tyrosine kinase, while its effects on multiple myeloma have not been well described. Here, we show that microRNA-21 is an oncogenic marker closely linked...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IOS Press
2018-01-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428317731369 |
| _version_ | 1819080071837646848 |
|---|---|
| author | Jing Ma Wei Gong Su Liu Qian Li Mengzheng Guo Jinhan Wang Suying Wang Naiyao Chen Yafei Wang Qiang Liu Hui Zhao |
| author_facet | Jing Ma Wei Gong Su Liu Qian Li Mengzheng Guo Jinhan Wang Suying Wang Naiyao Chen Yafei Wang Qiang Liu Hui Zhao |
| author_sort | Jing Ma |
| collection | DOAJ |
| description | The oncogenic microRNA-21 contributes to the pathogenesis of multiple myeloma. Ibrutinib (also referred to as PCI-32765), an inhibitor of Bruton’s tyrosine kinase, while its effects on multiple myeloma have not been well described. Here, we show that microRNA-21 is an oncogenic marker closely linked with progression of multiple myeloma. Moreover, ibrutinib attenuates microRNA-21 expression in multiple myeloma cells by inhibiting nuclear factor-κB and signal transducer and activator of transcription 3 signaling pathways. Taken together, our results suggest that ibrutinib is a promising potential treatment for multiple myeloma. Further investigation of mechanisms of ibrutinib function in multiple myeloma will be necessary to evaluate its use as a novel multiple myeloma treatment. |
| first_indexed | 2024-12-21T19:39:03Z |
| format | Article |
| id | doaj.art-b5460ecbb45b4e468343ed029db08c84 |
| institution | Directory Open Access Journal |
| issn | 1423-0380 |
| language | English |
| last_indexed | 2024-12-21T19:39:03Z |
| publishDate | 2018-01-01 |
| publisher | IOS Press |
| record_format | Article |
| series | Tumor Biology |
| spelling | doaj.art-b5460ecbb45b4e468343ed029db08c842022-12-21T18:52:32ZengIOS PressTumor Biology1423-03802018-01-014010.1177/1010428317731369Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-κB and STAT3Jing Ma0Wei Gong1Su Liu2Qian Li3Mengzheng Guo4Jinhan Wang5Suying Wang6Naiyao Chen7Yafei Wang8Qiang Liu9Hui Zhao10Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, ChinaTianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, ChinaTianjin Key Laboratory of Cancer Prevention and Therapy and Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, ChinaTianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, ChinaTianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, ChinaTianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, ChinaTianjin Key Laboratory of Food and Biotechnology, School of Biotechnology and Food Science, Tianjin University of Commerce, Tianjin, ChinaDepartment of Hematology and Tangshan Key Laboratory, Translational Medical Center, North China University of Science and Technology, Tangshan, Hebei, ChinaTianjin Key Laboratory of Cancer Prevention and Therapy and Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, ChinaTianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, ChinaDepartment of Hematology and Tangshan Key Laboratory, Translational Medical Center, North China University of Science and Technology, Tangshan, Hebei, ChinaThe oncogenic microRNA-21 contributes to the pathogenesis of multiple myeloma. Ibrutinib (also referred to as PCI-32765), an inhibitor of Bruton’s tyrosine kinase, while its effects on multiple myeloma have not been well described. Here, we show that microRNA-21 is an oncogenic marker closely linked with progression of multiple myeloma. Moreover, ibrutinib attenuates microRNA-21 expression in multiple myeloma cells by inhibiting nuclear factor-κB and signal transducer and activator of transcription 3 signaling pathways. Taken together, our results suggest that ibrutinib is a promising potential treatment for multiple myeloma. Further investigation of mechanisms of ibrutinib function in multiple myeloma will be necessary to evaluate its use as a novel multiple myeloma treatment.https://doi.org/10.1177/1010428317731369 |
| spellingShingle | Jing Ma Wei Gong Su Liu Qian Li Mengzheng Guo Jinhan Wang Suying Wang Naiyao Chen Yafei Wang Qiang Liu Hui Zhao Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-κB and STAT3 Tumor Biology |
| title | Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-κB and STAT3 |
| title_full | Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-κB and STAT3 |
| title_fullStr | Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-κB and STAT3 |
| title_full_unstemmed | Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-κB and STAT3 |
| title_short | Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-κB and STAT3 |
| title_sort | ibrutinib targets microrna 21 in multiple myeloma cells by inhibiting nf κb and stat3 |
| url | https://doi.org/10.1177/1010428317731369 |
| work_keys_str_mv | AT jingma ibrutinibtargetsmicrorna21inmultiplemyelomacellsbyinhibitingnfkbandstat3 AT weigong ibrutinibtargetsmicrorna21inmultiplemyelomacellsbyinhibitingnfkbandstat3 AT suliu ibrutinibtargetsmicrorna21inmultiplemyelomacellsbyinhibitingnfkbandstat3 AT qianli ibrutinibtargetsmicrorna21inmultiplemyelomacellsbyinhibitingnfkbandstat3 AT mengzhengguo ibrutinibtargetsmicrorna21inmultiplemyelomacellsbyinhibitingnfkbandstat3 AT jinhanwang ibrutinibtargetsmicrorna21inmultiplemyelomacellsbyinhibitingnfkbandstat3 AT suyingwang ibrutinibtargetsmicrorna21inmultiplemyelomacellsbyinhibitingnfkbandstat3 AT naiyaochen ibrutinibtargetsmicrorna21inmultiplemyelomacellsbyinhibitingnfkbandstat3 AT yafeiwang ibrutinibtargetsmicrorna21inmultiplemyelomacellsbyinhibitingnfkbandstat3 AT qiangliu ibrutinibtargetsmicrorna21inmultiplemyelomacellsbyinhibitingnfkbandstat3 AT huizhao ibrutinibtargetsmicrorna21inmultiplemyelomacellsbyinhibitingnfkbandstat3 |